OTCMKTS:HKMPY Hikma Pharmaceuticals (HKMPY) Stock Price, News & Analysis → Collect 10%+ Dividends from AI's Explosive Growth? (From The Oxford Club) (Ad) Free HKMPY Stock Alerts $50.66 0.00 (0.00%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$50.66▼$50.6650-Day Range$46.16▼$51.5552-Week Range$42.23▼$56.63Volume110 shsAverage Volume1,005 shsMarket CapitalizationN/AP/E Ratio16.37Dividend Yield0.63%Price TargetN/A Stock AnalysisStock AnalysisChartDividendHeadlinesShort InterestStock AnalysisChartDividendHeadlinesShort Interest Ad Stansberry ResearchPresident KamalaThe sneaky (yet 100% legal) way for Obama to return to power The ONLY way Democrats can keep the White House is to bring back Barack Obama. And there's a sneaky (yet 100% legal) way to achieve this. In fact, this disaster scenario is already underway. See what they're up to, and how you can get ready today.Here's the full video exposé. About Hikma Pharmaceuticals Stock (OTCMKTS:HKMPY)Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.Read More HKMPY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HKMPY Stock News HeadlinesApril 15, 2024 | finance.yahoo.comWith 52% institutional ownership, Hikma Pharmaceuticals PLC (LON:HIK) is a favorite amongst the big gunsFebruary 22, 2024 | msn.comHikma shares spike after pharma giant’s profit up 30 per centFebruary 21, 2024 | prnewswire.comHikma hosts White House Drug Policy Director Dr. Rahul Gupta at its Columbus, Ohio manufacturing facilityFebruary 5, 2024 | finanznachrichten.deHikma Pharmaceuticals USA Inc.: Hikma announces US launch of COMBOGESIC IVFebruary 5, 2024 | markets.businessinsider.comHikma Pharma Launches Pain Relief Injection COMBOGESIC IV In USFebruary 5, 2024 | finance.yahoo.comHikma announces US launch of COMBOGESIC® IVJanuary 22, 2024 | finance.yahoo.comActiv Surgical Announces Completion of First International Procedure Using Its ActivSight™ Intelligent LightJanuary 8, 2024 | finance.yahoo.comGuardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North AfricaNovember 6, 2023 | finance.yahoo.comHikma Pharmaceuticals PLC's (LON:HIK) institutional investors lost 5.8% over the past week but have profited from longer-term gainsAugust 17, 2023 | msn.comSK Biopharm inks license deal with Hikma's Middle East unitAugust 15, 2023 | marketwatch.comHikma Pharmaceuticals outperforms market despite losses on the dayAugust 8, 2023 | msn.comHikma Pharmaceuticals goes ex dividend tomorrowAugust 6, 2023 | finance.yahoo.comIs It Worth Considering Hikma Pharmaceuticals PLC (LON:HIK) For Its Upcoming Dividend?June 27, 2023 | thestreet.comHikma Trims Full-Year Revenue Guidance After Advair Diskus DelayJune 15, 2023 | finance.yahoo.comHikma exceeds 150 injectable medicines in the US with launch of Dobutamine Injection, USPMay 31, 2023 | uk.finance.yahoo.comFTSE 100: Ocado at risk, IMI in – how London Stock Exchange is set to reshuffle the indexMay 5, 2023 | marketwatch.comHikma Pharmaceuticals rises Friday, still underperforms marketMay 3, 2023 | marketwatch.comHikma Pharmaceuticals rises Wednesday, outperforms marketMarch 19, 2023 | finance.yahoo.comHikma Pharmaceuticals Full Year 2022 Earnings: EPS Misses ExpectationsFebruary 7, 2023 | uk.investing.comHikma Pharmaceuticals PLC (HIK)January 31, 2023 | marketwatch.comHikma Pharmaceuticals rises Tuesday, outperforms marketJanuary 24, 2023 | marketwatch.comHikma Pharmaceuticals falls Tuesday, underperforms marketDecember 27, 2022 | msn.comJunshi inks licensing deal with Hikma for toripalimab; FDA filing still under reviewDecember 26, 2022 | financialpost.comJunshi Biosciences and Hikma Sign Exclusive Licensing Agreement for Cancer Treatment Drug Toripalimab for the Middle East and North Africa RegionDecember 15, 2022 | marketwatch.comHikma Pharmaceuticals rises Thursday, outperforms marketSee More Headlines Company Calendar Ex-Dividend for 5/13 Dividend3/21/2024Dividend Payable5/13/2024Today6/14/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:HKMPY CUSIPN/A CIKN/A Webwww.hikma.com Phone442073992760FaxN/AEmployees9,100Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio16.37 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Key ExecutivesEngineer Said Samih Taleb Darwazah (Age 67)Executive Chairman Comp: $2.8MMr. Riad Ali Mishlawi (Age 60)CEO & Director Comp: $1.1MMr. Mazen Samih Taleb Darwazah (Age 66)Executive Vice Chairman & President of MENA Comp: $2.3MMr. Khalid Waleed Hosny Al Nabilsi (Age 52)Chief Financial Officer Patricia BousfieldChief Information OfficerMr. Guy FeatherstoneAssociate Director of Investor RelationsMr. Samuel ParkGeneral CounselMr. Bassam Wael Rushdi Kanaan CFA (Age 59)CPA, Executive Vice President of Corporate Development and M&A Mr. Hussein Omar ArkhaghaChief People OfficerMs. Susan RingdalExecutive Vice President of Strategic Planning & Global AffairsMore ExecutivesKey Competitors1933 IndustriesOTCMKTS:TGIFF4Cable TV InternationalOTCMKTS:CATV4Front VenturesOTCMKTS:FFNTFAB ScienceOTCMKTS:ABSCFAbacus Health ProductsOTCMKTS:ABAHFView All Competitors HKMPY Stock Analysis - Frequently Asked Questions How have HKMPY shares performed in 2024? Hikma Pharmaceuticals' stock was trading at $45.4110 on January 1st, 2024. Since then, HKMPY shares have increased by 11.6% and is now trading at $50.66. View the best growth stocks for 2024 here. Are investors shorting Hikma Pharmaceuticals? Hikma Pharmaceuticals saw a increase in short interest in May. As of May 15th, there was short interest totaling 200 shares, an increase of 100.0% from the April 30th total of 100 shares. Based on an average daily volume of 3,100 shares, the days-to-cover ratio is currently 0.1 days. View Hikma Pharmaceuticals' Short Interest. How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals? Hikma Pharmaceuticals announced a dividend on Wednesday, March 6th. Shareholders of record on Friday, March 22nd will be given a dividend of $0.92 per share on Monday, May 13th. The ex-dividend date is Thursday, March 21st. This is a positive change from the stock's previous dividend of $0.48. Read our dividend analysis for HKMPY. Is Hikma Pharmaceuticals a good dividend stock? Hikma Pharmaceuticals (OTCMKTS:HKMPY) pays an annual dividend of $0.32 per share and currently has a dividend yield of 0.65%. The dividend payout ratio is 10.34%. This payout ratio is at a healthy, sustainable level, below 75%. Read our dividend analysis for HKMPY. How do I buy shares of Hikma Pharmaceuticals? Shares of HKMPY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:HKMPY) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredBUY ALERT: Tiny tech play partners with US governmentThe Federal Reserve is rolling out a powerful new financial technology across the entire U.S. banking system. ...Stansberry Research | SponsoredTime is Running Out - June 25th Deadline Approaching!Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRIL...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Hikma Pharmaceuticals PLC You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Hikma Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.